736 related articles for article (PubMed ID: 30919899)
1. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
[TBL] [Abstract][Full Text] [Related]
2. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
[TBL] [Abstract][Full Text] [Related]
3. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
[TBL] [Abstract][Full Text] [Related]
4. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Emrich I; Mancia G; Redon J; Schmieder RE; Sliwa K; Lehrke M; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE
J Hypertens; 2021 Apr; 39(4):766-774. PubMed ID: 33560052
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke.
Böhm M; Schumacher H; Teo KK; Lonn EM; Lauder L; Mancia G; Redon J; Schmieder RE; Sliwa K; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE; Mahfoud F
J Hypertens; 2021 Aug; 39(8):1602-1610. PubMed ID: 34188004
[TBL] [Abstract][Full Text] [Related]
6. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Ukena C; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Marx N; Weber MA; Williams B; Yusuf S
Eur Heart J; 2020 Jan; 41(2):231-238. PubMed ID: 30590564
[TBL] [Abstract][Full Text] [Related]
7. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
Verdecchia P; Reboldi G; Angeli F; Trimarco B; Mancia G; Pogue J; Gao P; Sleight P; Teo K; Yusuf S
Hypertension; 2015 Jan; 65(1):108-14. PubMed ID: 25331850
[TBL] [Abstract][Full Text] [Related]
8. Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status.
Zhu J; Yang K; Liu W
J Clin Hypertens (Greenwich); 2024 May; 26(5):514-524. PubMed ID: 38552135
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
10. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
13. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.
Mancia G; Schumacher H; Böhm M; Redon J; Schmieder RE; Verdecchia P; Sleight P; Teo K; Yusuf S
Hypertension; 2017 Nov; 70(5):938-948. PubMed ID: 28974567
[TBL] [Abstract][Full Text] [Related]
14. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
17. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.
Bergmark BA; Scirica BM; Steg PG; Fanola CL; Gurmu Y; Mosenzon O; Cahn A; Raz I; Bhatt DL;
Eur Heart J; 2018 Jun; 39(24):2255-2262. PubMed ID: 29394350
[TBL] [Abstract][Full Text] [Related]
19. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
20. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
